All In Biotech

Drug Trial Radar · NCT06455826

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jun 13, 2024

Primary completion

Sep 24, 2025

Study completion Sep 24, 2025

Sponsor

Lead sponsor
PYC TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Conditions

  • Retinitis Pigmentosa 11
  • Retinal Degeneration
  • Eye Diseases
  • Retinal Disease
  • Retinal Dystrophies

Interventions

  • VP-001Drug

    A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence, severity, and relatedness of treatment-emergent ocular adverse events and treatment-emergent serious adverse eventsTime frame: over a 4-week post-dose period
  2. The incidence, severity, and relatedness of treatment-emergent ocular adverse eventsTime frame: over a 52-week period

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida Health

    Jacksonville, Florida

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

  • Oregon Health and Science University - Casey Eye Institute

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Baylor College of Medicine- Alkek Eye Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.